BED = nd(1 + d/(α/β)) | EQD2 = BED / (1 + 2/(α/β))
Compare radiotherapy fractionation schedules across tumor control (α/β = 10 Gy), late normal-tissue sparing (α/β = 3 Gy), and hypofractionated stereotactic protocols.
Educational Notice: This linear-quadratic (LQ) calculator is an academic medical physics and radiobiology study tool modeled on standard ICRU/AAPM equations. It is not intended for direct clinical treatment prescription without board-certified radiation oncology and medical physics verification.
Calculate BED & EQD2
Optional Isoeffective Comparison Regimen
Loading calculation...
Derivation & step-by-step evaluation
1. Total Physical Dose:D = n × d delivered over n equal fractions.
2. Biologically Effective Dose (BED): Derived from ln(S) = -n(αd + βd²) divided by -α, yielding BED = nd [1 + d / (α/β)]. Physically, BED equals the total dose required to produce the same surviving fraction if delivered in an infinite number of infinitesimally small fractions (d → 0).
3. Equivalent Dose in 2 Gy Fractions (EQD2): Equating the BED of a schedule to a standard 2 Gy per fraction regimen gives EQD2 × [1 + 2/(α/β)] = nd × [1 + d/(α/β)].
Formula & Variable Definitions
BED = n · d · (1 + d / (α/β)) | EQD2 = D · (d + α/β) / (2 + α/β)
Symbol
Quantity
Unit
n
Number of radiation fractions
dimensionless
d
Absorbed dose per fraction
Gy (J/kg)
α/β
Dose where linear (αD) and quadratic (βD²) cell kill are equal
Gy
BED
Biologically Effective Dose
Gyα/β
EQD2
Equivalent total dose in 2 Gy fractions
Gy
Physical Assumptions & Model Limits
The standard BED and EQD2 formulation assumes complete sublethal DNA damage repair between fractions separated by at least 6 to 24 hours, uniform dose distribution across the target volume, and negligible tumor repopulation over short overall treatment times. When comparing altered fractionation schedules spanning several weeks in rapidly proliferating tumors (such as head and neck squamous cell carcinoma or cervical cancer), a time-kickoff repopulation correction term -K · (T - T_k) is often subtracted from tumor BED.
Furthermore, at extreme stereotactic doses per fraction above approximately 10–15 Gy (SBRT/SRS), clonogenic survival curves often transition from a purely downward-curving quadratic shoulder toward a straighter high-dose tail governed by linear-quadratic-linear (LQL) or Universal Survival Curve kinetics, and indirect vascular/immune endothelial effects may supplement direct clonogenic kill.
Worked Clinical Example: Why α/β Drives Therapeutic Ratio
Compare 60 Gy in 30 fractions (2 Gy/fx) vs. 54 Gy in 3 fractions (18 Gy/fx) for a peripheral lung tumor (α/β = 10 Gy) adjacent to late-responding chest wall/lung parenchyma (α/β = 3 Gy).
Clinical Insight: Hypofractionation amplifies biological effect disproportionately more in low α/β tissues (late OARs ↑ 3.78×) than in high α/β tumors (↑ 2.10×) — explaining why SBRT requires steep image-guided dose gradients and strict normal-tissue sparing.
Common Exam & Clinical Calculation Mistakes
Never add BEDs computed with different α/β subscripts: Composite EBRT + brachytherapy or re-irradiation plans must convert each phase into identical α/β BED or EQD2 values before summing.
Late-responding OARs vs. tumor α/β: Spinal cord, optic nerve, rectum, and heart usually use α/β = 2–3 Gy, whereas rapidly dividing epithelial tumors typically use 10 Gy. Prostate cancer is a classic exception with low α/β ≈ 1.5 Gy, favoring hypofractionation.
EQD2 equals physical dose when d = 2 Gy: Always verify that a 2 Gy per fraction schedule returns EQD2 = n × 2 identically regardless of α/β.
BED represents the theoretical total dose needed if radiation were delivered in infinitesimally small fractions (d → 0), so its numerical value is always higher than conventional physical doses. EQD2 rescales BED into the equivalent total dose if delivered at 2 Gy per fraction, making it directly comparable to standard QUANTEC organ-at-risk constraints.
Why does prostate cancer benefit radiobiologically from hypofractionation?
Clinical data indicate prostate adenocarcinoma has an atypically low α/β ratio (~1.5 Gy), lower than adjacent late-responding rectal and bladder mucosa (α/β ≈ 3–5 Gy). Increasing dose per fraction therefore increases prostate BED faster than late normal-tissue BED.